CL2022000086A1 - Vacunas contra ehrlichia y composiciones inmunogénicas - Google Patents

Vacunas contra ehrlichia y composiciones inmunogénicas

Info

Publication number
CL2022000086A1
CL2022000086A1 CL2022000086A CL2022000086A CL2022000086A1 CL 2022000086 A1 CL2022000086 A1 CL 2022000086A1 CL 2022000086 A CL2022000086 A CL 2022000086A CL 2022000086 A CL2022000086 A CL 2022000086A CL 2022000086 A1 CL2022000086 A1 CL 2022000086A1
Authority
CL
Chile
Prior art keywords
ehrlichia
immunogenic compositions
vaccines
adjuvant
canis
Prior art date
Application number
CL2022000086A
Other languages
English (en)
Inventor
Jere W Mcbride
Paul J Dominowski
Suman Mahan
Jason J Millership
Duncan M Mwangi
Sharath Rai
Sharon M Wappel
Original Assignee
Res Found Dev
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Dev, Zoetis Services Llc filed Critical Res Found Dev
Publication of CL2022000086A1 publication Critical patent/CL2022000086A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1246—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Rickettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En este documento se proporcionan composiciones inmunogénicas que pueden ser utilizadas, en algunos aspectos, para inducir una respuesta inmune contra una Ehrlichia tal como Ehrlichia canis. En algunas modalidades, la composición inmunogénica comprende una bacterina de E. canis y/o adyuvante, tal como por ejemplo una emulsión o adyuvante liposomal. También se proporcionan métodos relacionados, como para el diagnóstico o la vacunación contra la ehrlichiosis.
CL2022000086A 2019-07-12 2022-01-12 Vacunas contra ehrlichia y composiciones inmunogénicas CL2022000086A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962873843P 2019-07-12 2019-07-12
US201962879762P 2019-07-29 2019-07-29
US202063049476P 2020-07-08 2020-07-08

Publications (1)

Publication Number Publication Date
CL2022000086A1 true CL2022000086A1 (es) 2022-09-30

Family

ID=71948757

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000086A CL2022000086A1 (es) 2019-07-12 2022-01-12 Vacunas contra ehrlichia y composiciones inmunogénicas

Country Status (10)

Country Link
US (1) US20220356231A1 (es)
EP (1) EP3996741A1 (es)
JP (1) JP2022540197A (es)
CN (1) CN114514238A (es)
AU (1) AU2020314625A1 (es)
BR (1) BR112022000347A2 (es)
CA (1) CA3146842A1 (es)
CL (1) CL2022000086A1 (es)
MX (1) MX2022000525A (es)
WO (1) WO2021011456A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
US7204992B2 (en) * 2002-11-04 2007-04-17 Clayton Foundation For Research P153 and P156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
CA2604855C (en) * 2005-04-04 2016-11-01 Idexx Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
EP1891095A2 (en) * 2005-06-16 2008-02-27 Research Development Foundation Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
US8389573B2 (en) * 2006-06-27 2013-03-05 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
JP5498164B2 (ja) * 2006-08-31 2014-05-21 リサーチ ディベロップメント ファウンデーション エーリキア・カニスの免疫反応性糖タンパク質ｇｐ１９
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
WO2010126993A1 (en) * 2009-04-28 2010-11-04 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
DK2575878T3 (en) * 2010-05-28 2018-08-13 Zoetis Belgium S A VACCINES INCLUDING CHOLESTEROL AND CPG AS THE ONLY ADJUVENT CARRIER MOLECULES
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
AU2013267716B2 (en) * 2012-05-31 2018-03-08 Zoetis Services Llc Vaccination with Canine Respiratory Coronavirus for protection against B. bronchiseptica infections
JP6586083B2 (ja) * 2013-09-19 2019-10-02 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
US11046734B2 (en) * 2018-07-27 2021-06-29 Research Development Foundation Chimeric immunogenic polypeptides

Also Published As

Publication number Publication date
AU2020314625A1 (en) 2022-02-03
EP3996741A1 (en) 2022-05-18
JP2022540197A (ja) 2022-09-14
BR112022000347A2 (pt) 2022-04-12
WO2021011456A1 (en) 2021-01-21
US20220356231A1 (en) 2022-11-10
CN114514238A (zh) 2022-05-17
CA3146842A1 (en) 2021-01-21
MX2022000525A (es) 2022-04-20

Similar Documents

Publication Publication Date Title
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
AR105470A1 (es) Métodos para inducir una respuesta inmune
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
CL2022000774A1 (es) Vacunas para vhb y métodos de tratamiento de vhb
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
CL2016002402A1 (es) Composiciones inmunológicas que contiene histophilus somni atenuado
PE20151588A1 (es) Vacuna contra el virus del dengue
CO2018003460A2 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
DOP2018000209A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
AR089995A1 (es) Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas
AR104271A1 (es) Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
CL2022000086A1 (es) Vacunas contra ehrlichia y composiciones inmunogénicas
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene